Clear Value Plus Reaches Milestone 100,000th Clinical Decision Recorded
“We are extremely proud to announce that Clear Value Plus has supported and informed providers recording more than 100,000 chemotherapy decisions,” said Dan Lodder, VP/GM, Technology Solutions, McKesson Specialty Health. “We are pleased to provide clinical content and technology that supports success in value-based programs, and we are committed to providing innovative tools to help improve patient outcomes and performance in these initiatives.”
“This breadth of utilization highlights that as healthcare continues to shift from fee-for-service, the NCCN Guidelines and Value Pathways powered by NCCN will become increasingly important for providers to access through integrated technology,” said Robert Carlson, M.D., CEO of NCCN.
Clear Value Plus supports participation in value-based care programs such as the Oncology Care Model and the MACRA Quality Payment Program. Clear Value Plus provides real-time reporting to demonstrate quality, including key performance metrics such as adherence, regimen utilization history and program participation—for an individual provider, a single site, or across the entire practice.
Clear Value Plus helps providers make informed decisions for their patients at the point of care. Benefits of Clear Value Plus include:
- Helping practices deliver quality cancer care through access to Value Pathways powered by NCCNTM and NCCN Guidelines® at the point of care
- Increasing financial transparency by providing cost effectiveness of different treatment options and minimizing exposure to denied claims by documenting adherence to evidence-based treatments
- Improving prior authorization and easing the burden of documentation by confirming regimen selections are on-guideline and on-pathway, automatically recording treatment decisions in the patient record of the practice’s integrated EHR, and collaborating with payers to opt out of prior authorization by demonstrating adherence to pathways
- Supporting participation in value-based care programs by helping to meet requirements of the Quality Programs through real-time reporting and confirmation that chosen therapies are consistent with nationally recognized clinical guidelines
McKesson Specialty Health provides strong and comprehensive practice management capabilities, value-based care expertise, and innovative technology solutions that are critical for community-based practices navigating today’s challenging healthcare landscape.
“Clear Value Plus plays a key role in a practice’s ability to provide quality care to their patients in real time as well as follow clinical guidelines to help them succeed in the numerous value-based care programs that are live today,” said Marcus Neubauer, M.D., medical director of Oncology Services for McKesson Specialty Health and The US Oncology Network. “Quality improvement programs and adherence to guidelines are now often requirements, and with Clear Value Plus, we can provide real-time feedback. For instance, in the 100,000 recorded decisions, we can report that 86% were concordant with NCCN Guidelines and 80% concordant with Value Pathways powered by NCCN. It’s powerful for practices to combine NCCN content with data, and serves as one of the many solutions McKesson Specialty Health offers to support the move to collaborative value-based care.”
About McKesson Specialty Health
McKesson Specialty Health, a division of McKesson Corporation, empowers the community patient care delivery system by helping community practices advance the science, technology and quality of care. Through innovative clinical research, business and operational solutions, facilitated by integrated technology systems, we focus on improving the financial health of our customers so they may provide the best care to their patients. For more information, visit www.mckessonspecialtyhealth.com.